Cardiac and Thoracic

 Adult Congenital Heart Disease Services (Levels 1 and 2) for people aged 16 and over, Service Specification (CP214), June 2022.pdf (PDF, 423Kb)
 Adult Thoracic Surgery, Service Specification (SS144), January 2026 (PDF, 581Kb)
 Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (all ages), Policy Position Statement (PP162), January 2019.pdf (PDF, 274Kb)
 Cardiac Surgery, Service Specification (SS205), July 2025.pdf (PDF, 1.0Mb)
 Complex Devices, Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure, Policy Position Statement (PP151), January 2019.pdf (PDF, 299Kb)
 Electrophysiology and Ablation Services (16 years and older), Commissioning policy (CP197a), January 2021.pdf (PDF, 347Kb)
 Electrophysiology and Ablation Services (16 years and older), Service Specification (CP197b), January 2021.pdf (PDF, 331Kb)
 Everolimus for the prevention of organ rejection following heart transplantation, Policy Position (PP103), July 2019.pdf (PDF, 164Kb)
 Extra Corporeal Membrane Oxygenation (ECMO) service for adults with cardiac failure, Policy Position Statement, (PPS102) July 2026.pdf (PDF, 396Kb)
 Obesity Surgery for Complex and Severe Obesity Level 4 (Adults), Commissioning Policy, (CP29a), March 2023.pdf (PDF, 316Kb)
 Obesity Surgery for Complex and Severe Obesity- Level 4 (Adults), Service Specification (CP29b), March 2023.pdf (PDF, 383Kb)
 Percutaneous Mitral Valve Leaflet repair for primary degenerative mitral regurgitation in adults, Policy Position Statement (PPS206), June 2021.pdf (PDF, 572Kb)
 Personalised External Aortic Root Support (PEARS) for surgical management of enlarged aortic root (adults), Policy Position Statement (PP104), March 2019.pdf (PDF, 195Kb)
 Revision Surgery for Severe and Complex Obesity (Adults), Commissioning Policy (CP259), May 2023.pdf (PDF, 406Kb)
 Selexipag for the Treatment of Pulmonary Arterial Hypertension (Adults), Policy Position (PP105), May 2019.pdf (PDF, 255Kb)
 Tafamidis for treating transthyretin amyloidosis with cardiomyopathy, Policy Position Statement (PPS306), April 2025.pdf (PDF, 437Kb)
 Trans-catheter Aortic Valve Implantation (TAVI) for Severe Symptomatic Aortic Stenosis (SSAS), Commissioning Policy (CP58), March 2019.pdf (PDF, 295Kb)